New hope for better calcium control in rare hormone disorder
Disease control
Not yet recruiting
This Phase 3 trial is testing whether higher daily doses of an investigational long-acting parathyroid hormone drug (palopegteriparatide) are safe and more effective for adults with hypoparathyroidism. The study aims to help participants maintain normal blood calcium levels while…
Phase: PHASE3 • Sponsor: Ascendis Pharma Bone Diseases A/S • Aim: Disease control
Last updated Apr 01, 2026 14:40 UTC